Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

110 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prediction of repeat-dose occupancy from single-dose data: characterisation of the relationship between plasma pharmacokinetics and brain target occupancy.
Abanades S, van der Aart J, Barletta JA, Marzano C, Searle GE, Salinas CA, Ahmad JJ, Reiley RR, Pampols-Maso S, Zamuner S, Cunningham VJ, Rabiner EA, Laruelle MA, Gunn RN. Abanades S, et al. Among authors: zamuner s. J Cereb Blood Flow Metab. 2011 Mar;31(3):944-52. doi: 10.1038/jcbfm.2010.175. Epub 2010 Oct 13. J Cereb Blood Flow Metab. 2011. PMID: 20940733 Free PMC article.
Adaptive-optimal design in PET occupancy studies.
Zamuner S, Di Iorio VL, Nyberg J, Gunn RN, Cunningham VJ, Gomeni R, Hooker AC. Zamuner S, et al. Clin Pharmacol Ther. 2010 May;87(5):563-71. doi: 10.1038/clpt.2010.9. Epub 2010 Mar 24. Clin Pharmacol Ther. 2010. PMID: 20336064
A pharmacokinetic PET study of NK₁ receptor occupancy.
Zamuner S, Rabiner EA, Fernandes SA, Bani M, Gunn RN, Gomeni R, Ratti E, Cunningham VJ. Zamuner S, et al. Eur J Nucl Med Mol Imaging. 2012 Feb;39(2):226-35. doi: 10.1007/s00259-011-1954-2. Epub 2011 Oct 13. Eur J Nucl Med Mol Imaging. 2012. PMID: 21993526
Full central neurokinin-1 receptor blockade is required for efficacy in depression: evidence from orvepitant clinical studies.
Ratti E, Bettica P, Alexander R, Archer G, Carpenter D, Evoniuk G, Gomeni R, Lawson E, Lopez M, Millns H, Rabiner EA, Trist D, Trower M, Zamuner S, Krishnan R, Fava M. Ratti E, et al. Among authors: zamuner s. J Psychopharmacol. 2013 May;27(5):424-34. doi: 10.1177/0269881113480990. Epub 2013 Mar 28. J Psychopharmacol. 2013. PMID: 23539641 Clinical Trial.
Target engagement and cellular fate of otelixizumab: a repeat dose escalation study of an anti-CD3ε mAb in new-onset type 1 diabetes mellitus patients.
Vlasakakis G, Napolitano A, Barnard R, Brown K, Bullman J, Inman D, Keymeulen B, Lanham D, Leirens Q, MacDonald A, Mezzalana E, Page K, Patel M, Savage CO, Zamuner S, van Maurik A. Vlasakakis G, et al. Among authors: zamuner s. Br J Clin Pharmacol. 2019 Apr;85(4):704-714. doi: 10.1111/bcp.13842. Epub 2019 Feb 5. Br J Clin Pharmacol. 2019. PMID: 30566758 Free PMC article. Clinical Trial.
110 results